Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast

Journal of Histochemistry and Cytochemistry

Volumn 63, Issue 6, 2015, Pages 408-416

  Perez, Amanda Arantes ^a   Balabram, Débora ^a   Rocha, Rafael Malagoli ^b   da Silva Souza, Átila ^a   Gobbi, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

biological markers; biomarkers; breast cancer; ductal carcinoma in situ

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P16; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CELL CYCLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; BREAST; BREAST TUMOR; PATHOLOGY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84930686091     PISSN: 00221554     EISSN: 15515044     Source Type: Journal    
DOI: 10.1369/0022155415576540     Document Type: Article

References (35)

1. Benson JR,Wishart GC.Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery.Lancet Oncol. 2013;14:348-357
2. Bryan BB,Schnitt SJ,Collins LC.Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621
3. Burstein HJ,Polyak K,Wong JS,Lester SC,Kaelin CM.Ductal carcinoma in situ of the breast.N Engl J Med. 2004;350:1430-1441
4. Carey LA,Perou CM,Livasy CA,Dressler LG,Cowan D,Conway K,Karaca G,Troester MA,Tse CK,Edmiston S,Deming SL,Geradts J,Cheang MC,Nielsen TO,Moorman PG,Easrp HS,Millikan RC.Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA. 2006;295:2492-2502
5. Controle de câncer. c2015. Informativo Vigilância do Câncer. Perfil da morbimortalidade brasileira do câncer de mama. Brazil: Ministério da Saúde [Accessed July 26, 2014]. http://bvsms.saude.gov.br/bvs/controle_cancer.
6. Dabbs DJ,Chivukula M,Carter G,Bhargava R.Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511
7. Generali D,Buffa FM,Deb S,Cummings M,Reid LE,Taylor M,Andreis D,Allevi G,Ferrero G,Byrne D,Martinotti M,Bottini A,Harris AL,Lakhani SR,Fox SB.COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.B J Cancer. 2014;111:46-54
8. Goldhirsch A,Winer EP,Coates AS,Gelber RD,Piccart-Gebhart M,Thürlimann B,Senn HJ.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Ann Oncol. 2013;24:2206-2223
9. Hammond MEH,Hayes DF,Wolff AC,Mangu PB,Temin S.American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.J Oncol Pract. 2010;6:195-197
10. Inwald EC,Klinkhammer-Schalke M,Hofstädter F,Zeman F,Loller M,Gerstenhauer M,Gerstenhauer M,Ortmann O.Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.Breast Cancer Res Treat. 2013;139:539-552
11. Johnson RH,Chien FL,Bleyer A.Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009.JAMA. 2013;309:800-805
12. Kerlikowske K,Molinaro AM,Gauthier ML,Berman HK,Waldman F,Bennington J,Sanchez H,Jimenez C,Stewart K,Chew K,Ljung BM,Tlsty TD.Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.J Natl Cancer Inst. 2010;102:627-637
13. 2012. IARC WHO Classification of Tumours of the Breast, 4th edition, Lyon: World Health Organization.Lakhani SEllis JSchnitt STan Pvan de Vijver MJ, ed. Lyon: World Health Organization; 2012:
14. Lari AS,Kuerer HM.Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.J Cancer. 2011;2:232-261
15. Leo C,Faber S,Hentschel B,Höckel M,Horn LC.The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.Ann Diagn Pathol. 2006;10:327-332
16. Livasy CA,Perou CM,Karaca G,Cowan DW,Maia D,Jackson S,Tse CK,Nyante S,Millikan RC.Identification of a basal-like subtype of breast ductal carcinoma in situ.Hum Pathol. 2007;38:197-204
17. Lopez-Garcia MA,Geyer FC,Lacroix-Triki M,Marchió C,Reis-Filho JS.Breast cancer precursors revisited: molecular features and progression pathways.Histopathology. 2010;57:171-192
18. Nielsen TO,Hsu FD,Jensen K,Cheang M,Karaca G,Hu Z,Hernandez-Boussard T,Livasy C,Cowan D,Dressler L,Akslen LA,Ragaz J,Gown AM,Gilks CB,van de,Rijn M,Perou CM.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res. 2004;10:5367-5374
19. Nofech-Mozes S,Spayne J,Rakovitch E,Hanna W.Prognostic and predictive molecular markers in DCIS: a review.Adv Anat Pathol. 2005;12:256-264
20. O’Sullivan MJ,Morrow M.Ductal carcinoma in situ--current management.Surg Clin North Am. 2007;87:333-351
21. Paredes J,Lopes N,Milanezi F,Schmitt FC.P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.Virchows Arch. 2007;450:73-80
22. Perez AA,Rocha RM,Balabram D,Souza AS,Gobbi H.Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.Clinics. 2013;68:674-678
23. Perou CM,Sorlie T,Eisen MB,van de,Rijn M,Jeffrey SS,Rees CA,Pollack JR,Ross DT,Johnsen H,Akslen LA,Fluge O,Pergamenschikov A,Williams C,Zhu SX,Lonning PE,Borresen-Dale AL,Brown PO,Botstein D.Molecular portraits of human breast tumours.Nature. 2000;406:747-752
24. Provenzano E,Hopper JL,Giles GG,Marr G,Venter DJ,Armes JE.Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.Eur J Cancer. 2003;39:622-630
25. Rakovitch E,Nofech-mozes S,Hanna W,Narod S,Thiruchelvam D,Saskin R,Spayne J,Taylor C,Paszat L.HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.Br J Cancer. 2012;106:1160-1165
26. Ristimäki A,Sivula A,Lundin J,Lundin M,Salminen T,Haglund C,Joensuu H,Isola J.Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.Cancer Res. 2002;62:632-635
27. Ross DS,Wen YH,Brogi E.Ductal carcinoma in situ: morphology-based knowledge and molecular advances.Adv Anat Pathol. 2013;20:205-216
28. Siziopikou KP.Ductal carcinoma in situ of the breast: current concepts and future directions.Arch Pathol Lab Med. 2013;137:462-466
29. Sorlie T,Tibshirani R,Parker J,Hastie T,Marron JS,Nobel A,Deng S,Johnsen H,Pesich R,Geisler S,Demeter J,Perou CM,Lonning PE,Brown PO,Borresen-Dale AL,Botstein D.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA. 2003;100:8418-8423
30. Tamimi RM,Baer HJ,Marotti J,Galan M,Galaburda L,Fu Y,Deitz AC,Connolly JL,Schnitt SJ,Colditz GA,Collins LC.Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.Breast Cancer Res. 2008;10:R67
31. Tipos de câncer. Breast. c1996-2015. Rio de Janeiro: INCA - Ministério da Saúde [Accessed July 26, 2014]. http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/mama.
32. VandenBussche CJ,Elwood H,Cimino-Mathews A,Bittar Z,Illei PB,Warzecha HN.Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.Hum Pathol. 2013;44:2487-2493
33. Wang SY,Shamliyan T,Virnig BA,Kane R.Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.Breast Cancer Res Treat. 2011;127:1-14
34. Witkiewicz AK,Rivadeneira DB,Ertel A,Kline J,Hyslop T,Schwartz GF,Fortina P,Knudsen ES.Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.Am J Pathol. 2011;179:1171-1178
35. Wolff AC,Hammond MEH,Hicks DG,Dowsett M,McShane LM,Allison KH,Allred DC,Bartlett JM,Bilous M,Fitzgibbons P,Hanna W,Jenkins RB,Mangu PB,Paik S,Perez EA,Press MF,Spears PA,Vance GH,Viale G,Hayes DF.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol. 2013;31:3997-4013